Opus Genetics to present topline Phase 1/2 OPGx-BEST1 gene therapy data on September 9, 2026, during investor call.
Quiver AI Summary
Opus Genetics, Inc. has announced that it will present topline data from Cohort 1 of its Phase 1/2 study of the OPGx-BEST1 gene therapy program during an investor conference call and webcast scheduled for September 9, 2026, at 8:00 a.m. ET. This gene therapy aims to address BEST1-related inherited retinal diseases and is part of a broader effort by Opus Genetics to develop treatments for various inherited retinal disorders. In addition to the investor presentation, the company will share the full clinical dataset and additional analyses at several upcoming medical conferences, including Euretina events and Retina in Rio. Opus Genetics focuses on developing one-time gene therapies to restore vision, with a pipeline that includes multiple AAV-based programs targeting various genetic conditions affecting the retina.
Potential Positives
- Opus Genetics is set to present topline data from its Phase 1/2 OPGx-BEST1 gene therapy program, indicating progress in their clinical development efforts.
- The upcoming presentations at major medical conferences demonstrate the company's commitment to transparency and stakeholder engagement regarding its clinical findings.
- The OPGx-BEST1 therapy targets specific inherited retinal diseases, showcasing the company's focus on innovative treatments for severe conditions that currently have limited options.
- Opus Genetics is advancing a comprehensive pipeline of seven gene therapy programs, indicating a robust research and development strategy to address various genetic retinal disorders.
Potential Negatives
- None
FAQ
When will Opus Genetics present the OPGx-BEST1 data?
Opus Genetics will present topline data during an investor conference call on September 9, 2026, at 8:00 a.m. ET.
Where can I watch the investor conference webcast?
The live webcast will be available in the Investors section of the Opus Genetics website.
What is OPGx-BEST1 designed to treat?
OPGx-BEST1 is designed to treat BEST1-related inherited retinal diseases, including BVMD and ARB.
What medical meetings will Opus Genetics attend?
Opus Genetics will present at medical meetings including Euretina and Retina in Rio later in 2026.
What is the goal of the BIRD-1 study?
The BIRD-1 study aims to evaluate the safety and efficacy of OPGx-BEST1 gene therapy in adults with BVMD or ARB.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRD Insider Trading Activity
$IRD insiders have traded $IRD stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $IRD stock by insiders over the last 6 months:
- FIGHTING BLINDNESS RETINAL DEGENERATION FUND FOUNDATION sold 1,700,000 shares for an estimated $7,394,999
- GEORGE MAGRATH (Chief Executive Officer) has made 0 purchases and 3 sales selling 43,424 shares for an estimated $204,899.
- ROBERT E. GAGNON (Chief Financial Officer) has made 0 purchases and 2 sales selling 15,625 shares for an estimated $63,599.
- BENJAMIN R YERXA (President) has made 0 purchases and 2 sales selling 14,899 shares for an estimated $61,185.
- ASHWATH JAYAGOPAL (Chief Scientific & Dev. Ofc.) has made 0 purchases and 2 sales selling 11,261 shares for an estimated $58,201.
- JOSEPH K SCHACHLE (Chief Operating Officer) has made 0 purchases and 3 sales selling 13,060 shares for an estimated $57,697.
- RABOURN AMY ZAREMBA (Head of Fin. Quality Assurance) has made 0 purchases and 2 sales selling 4,457 shares for an estimated $23,309.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IRD Revenue
$IRD had revenues of $755K in Q2 2026. This is a decrease of -73.8% from the same period in the prior year.
You can track IRD financials on Quiver Quantitative's IRD stock page.
You can access data on IRD stock through the Quiver Quantitative API.
$IRD Hedge Fund Activity
We have seen 69 institutional investors add shares of $IRD stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 3,100,000 shares (-64.8%) from their portfolio in Q1 2026, for an estimated $14,105,000
- BLACKROCK, INC. added 2,968,747 shares (+2009.4%) to their portfolio in Q2 2026, for an estimated $12,201,550
- TRAILS EDGE CAPITAL PARTNERS, LP added 2,743,658 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,276,434
- GREAT POINT PARTNERS LLC added 1,970,187 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,097,468
- PERCEPTIVE ADVISORS LLC removed 1,835,842 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,545,310
- GOLDMAN SACHS GROUP INC added 1,200,420 shares (+367.3%) to their portfolio in Q2 2026, for an estimated $4,933,726
- SUMMITTX CAPITAL, L.P. added 1,007,351 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,140,212
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IRD Price Targets
Multiple analysts have issued price targets for $IRD recently. We have seen 10 analysts offer price targets for $IRD in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Thomas Shrader from BTIG set a target price of $12.0 on 07/06/2026
- Andreas Argyrides from Chardan Capital set a target price of $13.0 on 07/06/2026
- Matthew Caufield from HC Wainwright & Co. set a target price of $8.0 on 06/17/2026
- Jonathan Wolleben from Citizens set a target price of $11.0 on 06/15/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $16.0 on 06/04/2026
- Lili Nsongo from Leerink Partners set a target price of $10.0 on 05/21/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $15.0 on 03/30/2026
Full Release
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET
Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.
The Company also plans to present the full clinical dataset and additional analyses from the OPGx-BEST1 program at several upcoming medical conferences.
Investor Conference Call and Webcast
Opus Genetics will host an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET to present topline data from Cohort 1 of the Phase 1/2 clinical study of OPGx-BEST1.
Date:
Wednesday, September 9, 2026
Time:
8:00 a.m. ET
Webcast:
Opus Genetics Investor Events
A live webcast and accompanying presentation will be available in the Investors section of the Company’s website. A replay will be available following the event.
Upcoming Conference Presentations
Euretina Innovation Spotlight (EIS)
Date: Wednesday, September 30, 2026
Time: 14:20-14:56 CEST
Presenter: Ben Yerxa
Title: Advancing the Future of IRDs: Opus Genetics Clinical Development Update
Euretina 2026
Date: Sunday, October 4, 2026
Time: 13:15-13:21 CEST
Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, Casey Eye Institute, School of Medicine
Title: Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
Retina in Rio
Date: Wednesday, October 14, 2026
Title: Structure-Function Correlation of EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy: Results from the Phase 1/2 BIRD-1 Study of OPGx-BEST1 Gene Therapy
Presenter: George Magrath, M.D, CEO, Opus Genetics
Title: Near Normalization of Cone Sensitivity using Gene Augmentation in Children with LCA5
Presenter: Rodrigo Jorge, M.D., Ph.D., Head of Ophthalmology Department at University of São Paulo
FLORetina Presentation
Title: Phase 1/2 Cohort 1 3M Results of OPGx-BEST1 Gene Therapy in Patients with BVMD and ARB Due to BEST1 Mutations
Presenter: Aaron Nagiel, M.D., Ph.D.
About OPGx-BEST1
OPGx-BEST1 is an investigational gene therapy designed to address the underlying genetic cause of BEST1-related inherited retinal diseases, including BVMD and ARB. OPGx-BEST1 uses an AAV vector to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells. The ongoing BIRD-1 study is an adaptive, open-label Phase 1/2 clinical trial evaluating the safety and efficacy of single-eye subretinal administration of OPGx-BEST1 in adults with BVMD or ARB.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com .
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
[email protected]
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
